Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Pacemaker-Based Cardiac Neuromodulation Therapy in Patients With Hypertension: A Pilot Study

Z. Kalarus, B. Merkely, P. Neužil, M. Grabowski, P. Mitkowski, G. Marinskis, A. Erglis, J. Kaźmierczak, T. Sturmberger, A. Sokal, S. Pluta, L. Gellér, I. Osztheimer, F. Malek, A. Kolodzińska, Y. Mika, SJ. Evans, HM. Hastings, D. Burkhoff, KH. Kuck

. 2021 ; 10 (16) : e020492. [pub] 20210813

Language English Country Great Britain

Document type Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22003920

Background In prior unblinded studies, cardiac neuromodulation therapy (CNT) employing a sequence of variably timed short and longer atrioventricular intervals yielded sustained reductions of systolic blood pressure (SBP) in patients with hypertension. The effects of CNT on SBP were investigated in this double-blind randomized pilot study. Methods and Results Eligible patients had daytime ambulatory SBP (aSBP) ≥130 mm Hg and office SBP ≥140 mm Hg despite taking ≥1 antihypertensive medication, and an indication for a dual-chamber pacemaker. Patients underwent Moderato device implantation, which was programmed as a standard pacemaker during a 1-month run-in phase. Patients whose daytime aSBP was ≥125 mm Hg at the end of this period were randomized (1:1, double blind) to treatment (CNT) or control (CNT inactive). The primary efficacy end point was the between-group difference of the change in 24-hour aSBP at 6 months. Of 68 patients initially enrolled and who underwent implantation with the Moderato system, 47 met criteria for study continuation and were randomized (26 treatment, 21 control). The mean age was 74.0±8.7 years, 64% were men, left ventricular ejection fraction was 59.2%±5.7%, and aSBP averaged 141.0±10.8 mm Hg despite the use of 3.3±1.5 antihypertensive medications; 81% had isolated systolic hypertension. Six months after randomization, aSBP was 11.1±10.5 mm Hg (95% CI, -15.2 to -8.1 mm Hg) lower than prerandomization in the treatment group compared with 3.1±9.5 mm Hg (-7.4 to 1.2 mm Hg) lower in controls, yielding a net treatment effect of 8.1±10.1 mm Hg (-14.2 to -1.9 mm Hg) (P=0.012). There were no Moderato device- or CNT-related adverse events. Conclusions CNT significantly reduced 24-hour aSBP in patients with hypertension with a clinical indication for a pacemaker. The majority of patients had isolated systolic hypertension, a particularly difficult group of patients to treat. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02837445.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003920
003      
CZ-PrNML
005      
20220526085255.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1161/JAHA.120.020492 $2 doi
035    __
$a (PubMed)34387126
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kalarus, Zbigniew $u Department of Cardiology DMS in ZabrzeMedical University of Silesia Katowice Poland
245    10
$a Pacemaker-Based Cardiac Neuromodulation Therapy in Patients With Hypertension: A Pilot Study / $c Z. Kalarus, B. Merkely, P. Neužil, M. Grabowski, P. Mitkowski, G. Marinskis, A. Erglis, J. Kaźmierczak, T. Sturmberger, A. Sokal, S. Pluta, L. Gellér, I. Osztheimer, F. Malek, A. Kolodzińska, Y. Mika, SJ. Evans, HM. Hastings, D. Burkhoff, KH. Kuck
520    9_
$a Background In prior unblinded studies, cardiac neuromodulation therapy (CNT) employing a sequence of variably timed short and longer atrioventricular intervals yielded sustained reductions of systolic blood pressure (SBP) in patients with hypertension. The effects of CNT on SBP were investigated in this double-blind randomized pilot study. Methods and Results Eligible patients had daytime ambulatory SBP (aSBP) ≥130 mm Hg and office SBP ≥140 mm Hg despite taking ≥1 antihypertensive medication, and an indication for a dual-chamber pacemaker. Patients underwent Moderato device implantation, which was programmed as a standard pacemaker during a 1-month run-in phase. Patients whose daytime aSBP was ≥125 mm Hg at the end of this period were randomized (1:1, double blind) to treatment (CNT) or control (CNT inactive). The primary efficacy end point was the between-group difference of the change in 24-hour aSBP at 6 months. Of 68 patients initially enrolled and who underwent implantation with the Moderato system, 47 met criteria for study continuation and were randomized (26 treatment, 21 control). The mean age was 74.0±8.7 years, 64% were men, left ventricular ejection fraction was 59.2%±5.7%, and aSBP averaged 141.0±10.8 mm Hg despite the use of 3.3±1.5 antihypertensive medications; 81% had isolated systolic hypertension. Six months after randomization, aSBP was 11.1±10.5 mm Hg (95% CI, -15.2 to -8.1 mm Hg) lower than prerandomization in the treatment group compared with 3.1±9.5 mm Hg (-7.4 to 1.2 mm Hg) lower in controls, yielding a net treatment effect of 8.1±10.1 mm Hg (-14.2 to -1.9 mm Hg) (P=0.012). There were no Moderato device- or CNT-related adverse events. Conclusions CNT significantly reduced 24-hour aSBP in patients with hypertension with a clinical indication for a pacemaker. The majority of patients had isolated systolic hypertension, a particularly difficult group of patients to treat. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02837445.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a krevní tlak $7 D001794
650    12
$a kardiostimulace umělá $x škodlivé účinky $7 D002304
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdce $x inervace $7 D006321
650    12
$a srdeční frekvence $7 D006339
650    _2
$a lidé $7 D006801
650    _2
$a hypertenze $x diagnóza $x patofyziologie $x terapie $7 D006973
650    _2
$a mužské pohlaví $7 D008297
650    12
$a kardiostimulátor $7 D010138
650    _2
$a pilotní projekty $7 D010865
650    _2
$a prospektivní studie $7 D011446
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a funkce levé komory srdeční $7 D016277
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Merkely, Béla $u Heart and Vascular Center Semmelweis University Budapest Hungary
700    1_
$a Neužil, Petr $u Department of Cardiology Na Homolce Hospital Prague Czech Republic
700    1_
$a Grabowski, Marcin $u 1st Chair and Department of Cardiology Medical University of Warsaw Poland
700    1_
$a Mitkowski, Przemysław $u 1st Department of Cardiology Karol Marcinkowski University of Medical Sciences Poznań Poland
700    1_
$a Marinskis, Germanas $u Department of Cardiovascular Diseases Centre for Cardiology and Angiology Vilnius University Vilnius Lithuania
700    1_
$a Erglis, Andrejs $u Pauls Stradins Clinical University Hospital University of Latvia Riga Latvia
700    1_
$a Kaźmierczak, Jarosław $u Department of Cardiology Pomeranian Medical University Szczecin Poland
700    1_
$a Sturmberger, Thomas $u Interne 2 - Kardiologie, Angiologie & Interne Intensivmedizin Ordensklinikum Linz GmbH Elisabethinen Linz Austria
700    1_
$a Sokal, Adam $u Department of Cardiology DMS in ZabrzeMedical University of Silesia Katowice Poland
700    1_
$a Pluta, Slawomir $u Department of Cardiology DMS in ZabrzeMedical University of Silesia Katowice Poland
700    1_
$a Gellér, László $u Heart and Vascular Center Semmelweis University Budapest Hungary
700    1_
$a Osztheimer, István $u Heart and Vascular Center Semmelweis University Budapest Hungary
700    1_
$a Malek, Filip $u Department of Cardiology Na Homolce Hospital Prague Czech Republic
700    1_
$a Kolodzińska, Agnieszka $u 1st Chair and Department of Cardiology Medical University of Warsaw Poland
700    1_
$a Mika, Yuval $u Orchestra Biomed New York NY
700    1_
$a Evans, Steven J $u Orchestra Biomed New York NY
700    1_
$a Hastings, Harold M $u Division of Science, Mathematics and Computing Bard College at Simon's Rock Great Barrington MA $u Department of Physics and Astronomy Hofstra University Hempstead NY
700    1_
$a Burkhoff, Daniel $u Cardiovascular Research Foundation New York NY
700    1_
$a Kuck, Karl-Heinz, $u LANS Cardio Hamburg Germany $d 1952- $7 xx0273250
773    0_
$w MED00188127 $t Journal of the American Heart Association $x 2047-9980 $g Roč. 10, č. 16 (2021), s. e020492
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34387126 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220526085249 $b ABA008
999    __
$a ok $b bmc $g 1751397 $s 1155069
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 10 $c 16 $d e020492 $e 20210813 $i 2047-9980 $m Journal of the American Heart Association $n J Am Heart Assoc $x MED00188127
LZP    __
$a Pubmed-20220113
Back

Find record

Citation metrics

Logged in users only

Archiving options